| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 582.64 | 34.8% | 3.4% |
| Total Income | 590.70 | 36.8% | 5.1% |
| Expenditure | 514.53 | 38.6% | 15.0% |
| PBT | 76.17 | 31.4% | 33.5% |
| Net Profit | 61.12 | 27.5% | 30.8% |
| OPM | 19.42% | 3.60pp | 6.41pp |
| NPM | 10.35% | 0.75pp | 5.36pp |
| EPS | 6.74 | 27.4% | 30.9% |
Aarti Pharmalabs: FY26 Revenue ₹1797.55 Mn, PAT ₹176.2 Mn
25 May 2026 · 25 May, 9:21 pm
Summary
Aarti Pharmalabs Limited reported a mixed performance for the fourth quarter and full Financial Year 2026. While Q4 FY26 revenue from operations grew by 9.45% year-on-year to ₹579.70 crore, net profit for the quarter saw a substantial decline of 30.18% to ₹62.03 crore. For the full fiscal year, the company posted a modest 1.48% increase in revenue from operations, totaling ₹1,797.55 crore. However, full-year net profit witnessed a significant 31.45% drop to ₹176.20 crore. The Board also recommended a final dividend of ₹2/- per equity share for FY26, subject to shareholder approval.
Key Highlights
- 1
Revenue from Operations for Q4 FY26 increased by 9.45% year-on-year to ₹579.70 crore.
- 2
Net Profit for Q4 FY26 declined significantly by 30.18% year-on-year to ₹62.03 crore.
- 3
For the full Financial Year 2026, Revenue from Operations recorded a modest growth of 1.48% year-on-year, reaching ₹1,797.55 crore.
- 4
Full-year Net Profit for FY26 sharply decreased by 31.45% to ₹176.20 crore compared to the previous fiscal year.
- 5
Basic Earnings Per Share (EPS) for Q4 FY26 was ₹6.84, with the full-year FY26 Basic EPS at ₹19.44.
- 6
The Board of Directors recommended a Final Dividend of ₹2/- per Equity Share for the Financial Year ended March 31, 2026.
Informational and educational content only. Not investment advice.